PRO-1107

N/A

Report date: 2026/03/11 20:02:12

Base Information

Drug NamePRO-1107
Drug Alias NamePRO-1107GEN-1107
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibodyBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > MMAE payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linker +[4] 
Mechanisms of ActionAnti-PTK7
TargetsProtein-tyrosine kinase 7
Therapy Area/IndicationsSolid tumoursEndometrial NeoplasmsCarcinoma, Non-Small-Cell Lung +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaDiscontinued
Originator CompaniesProfoundBio (Suzhou) Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesN/A
Inactive CompaniesProfoundBio (Suzhou) Co LtdGenmab A/S
Active IndicationsN/A
Inactive IndicationsSolid tumoursEndometrial NeoplasmsCarcinoma, Non-Small-Cell Lung +[8] 

Other Information

ATC CodeN/A
Related LinksN/A